Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1998-03-17
2000-12-26
Bansal, Geetha P.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
53038815, 5303882, 53038822, 5303888, 53038885, 5303897, 4241301, 4241311, 4241431, 4241521, 4241551, 4241561, 4241811, 4241831, 435330, 435334, A61K 39395, C07K 1600, C07K 1628, C07K 1630, C12N 512
Patent
active
061654647
ABSTRACT:
A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
REFERENCES:
patent: 4699877 (1987-10-01), Cline et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4906646 (1990-03-01), Honn et al.
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 4957735 (1990-09-01), Huang
patent: 4963354 (1990-10-01), Shepard et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5108934 (1992-04-01), Rokugawa et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5288477 (1994-02-01), Bacus
patent: 5308626 (1994-05-01), Landucci et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5470571 (1995-11-01), Herlyn et al.
patent: 5604107 (1997-02-01), Carney et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5747261 (1998-05-01), King et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5824311 (1998-10-01), Green et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 5985553 (1999-11-01), King et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6054561 (2000-04-01), Ring
Reddel et al., "Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen" Cancer Research 45(4):1525-1531 (Apr. 1985).
Zhang et al., "Shared antigenic epitopes and pathobiological functions of anti-p185.sup.her2
eu monoclonal antibodies" Experimental and Molecular Pathology 67:15-25 (1999).
DiFiore et al., "erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells" Science 237(4811):178-182 (Jul. 10, 1987).
Disis et al., "Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients with Breast Cancer" Cancer Research 54:16-20 (Jan. 1, 1994).
"Herceptin (Trastuzumab)" (Product Information) (1998).
Holtz, Andrew, "Herceptin: An Entirely New Weapon Against Cancer" Exclusive Report from the 1998 ASCO Meeting (1998).
Press et al., "Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissue" Oncogene 5:953-962 (1990).
Stedman Medical Dictionary 25th Edition:1606.
Goding Monoclonal Antibodies Principles and Practice 2.sup.nd Ed Acad Press (1986) pp. 11, 125, 126.
Aboud-Pirak et al., "Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma In Vitro and in Nude Mice" Journal of the National Cancer Institute 80(20):1605-1611 (Dec. 21, 1988).
Akiyama et al., "Potentation of Cytotoxic Activity of Immunotoxins on Cultured Human Cells" Cancer Research 45:1005-1007 (1985).
Akiyama et al., "The product of the human c-erbB-2 Gene: a 185-Kilodalton Glycoprotein with tyrosine Kinase Activity" Science 232:1644-1646 (1986).
Arteaga et al., "Antibodies Against p185/HER2 Enhance Etoposide-Induced Cytotoxicity Against Human Breast Carcinoma Cells" Proceedings of ASCO-29th Annual Meeting (Abstract #101), Orlando, FL 12:75 (1993).
Ballet et al., "Evaluation of a "Nude" Mouse-Human Tumor Panel as a Predictive Secondary Screen for Cancer Chemotherapeutic Agenst" J. Natl. Canc. Inst 63(5):1185-1188 (1979).
Bargmann et al., "Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185" Cell 45:649-659 (Jun. 6, 1986).
Bargmann et al., "The neu Oncogene Encodes an Epidermal Growth Factor Receptor-related Protein" Nature 319:226-230 (Jan. 16, 1986).
Baselga et al., "Anti Her2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" Proceedings of ASCO-13th Annual Meeting (Abstract #53), Dallas, TX 13:63 (1994).
Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185/HER2 Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer" J. Clin. Oncol. 14(3):737-744 (1996).
Baselga et al., "Receptor Blockade With Monoclonal Antibodies as Anti-Cancer Therapy" Pharmac. Ther. 64:127-154 (1994).
Beguinot et al., "Down-Regulation of the Epidermal Growth Factor Receptor in KB Cells is Due to Receptor Internalization and Subsequent Degradation in Lysozymes" Proc. Natl. Acad. Sci. USA 81(8):2384-2388 (1984).
Bernards et al., "Effective Tumor Immunotherapy Directed Against an Oncogene-encoded Product Using a Vaccinia Virus Vector" Proc. Natl. Acad. Sci. USA 84:6854-6858 (Oct. 1987).
Bjorn et al., "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins" Cancer Research 45:1214-1221 (1985).
Bucholtz, J.D., "Radiolabeled Antibody Therapy" Semin. Oncol. Nurs. (abstract only) 3(1):67-73 (1987).
Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" Monoclonal Antibodies and Cancer Therapy, Reisfeld et al., New York:Alan R. Liss, Inc. pp. 77-96 (1985).
Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene" Science 230:1132-1139 (1985).
De Santes et al., "Radiolabeled Antibody Targeting of the HER-2
eu Oncoprotein-1" Cancer Research 52:1916-1923 (1992).
Douillard et al., "Radioimmunotection of Human Tumors with Radiolabeled Monoclonal Antibodies" Oncogenes to Tumor Antigens, Geraldo et al. (eds.), Elsevier Sci. Publ. (1985).
Drebin et al., "Development of Monoclonal Antibodies Reactive with the Product of the neu Oncogene" Symposium on Fundamental Cancer Research 38:277-289 (1986).
Drebin et al., "Down-Modulation of an Oncogene Protein Product an Reversion of the Transformed Phenotype by Monoclonal Antobodies" Cell 41(3):695-706 (1985).
Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" Proc. Natl. Acad. Sci. 83:9129-9133 (1986).
Drebin et al., "Monoclonal Antibodies Identify a Cell-surface Antigen Associated with an Activated Cellular Oncogene" Nature 312:545-548 (Dec. 6, 1984).
Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" Oncogene 2:273-277 (1988).
Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" Oncogene 2(4):387-394 (1988).
Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product" Cancer Research 50:1550-1558 (Mar. 1, 1990).
Frankel et al., "Tissue Distribution of Breast Cancer--Associated Antigens Defined by Monoclonal Antibodies" Journal of Biological Response Modifers 4:273-286 (1985).
Fukushige et al., "Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosomes 17 and its Amplification in a Gastric Cancer Cell Line" Molecular & Cellular Biology 6(3):955-58 (1986).
Gill et al., "Monoclonal Anti-epidermal Growth Factor Receptor Antibodies Which are Inhibitors of Epidermal Growth Factor Binding and Antagonists of Epidermal Growth Factor-stimulated Tyrosine Kinase Activity" Journal of Biological Chemistry 259:7755-60 (1984).
Glassy et al., "Genetically Stable Human Hybridomas Secreting Tumor-Reactive Human Monoclonal IgM" Cancer Investigation 5:449-457 (1987).
Hancock et al., "A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines" Cancer Research 51:4575-4580 (Sep. 1, 1991).
Hudziak et al., "Amplified Expression of the HER2/ERBB2 Oncogene Induces Resistance to Tumor Necrosis Factor .alpha. in NIH 3T3 Cells" Proc. Natl. Acad. Sci. USA 85:5102-5106 (1988).
Hudziak et al., "Increased expression of the put
Fendly Brian M.
Hudziak Robert M.
Shepard H. Michael
Ullrich Axel
Bansal Geetha P.
Genetech, Inc.
Lee Wendy M.
LandOfFree
Monoclonal antibodies directed to the HER2 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies directed to the HER2 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies directed to the HER2 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-991686